IKS Health announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. Consolidated total income reached ₹8,205.03 million for the quarter. The company reported a consolidated profit for the period of ₹1,833.28 million. Standalone total income stood at ₹4,054.09 million with a profit for the period of ₹1,462.40 million.
Financial Performance Overview
IKS Health has released its unaudited financial results for Q3 2026, showcasing its performance for the quarter and the nine-month period ending December 31, 2025. The announcement provides insights into both consolidated and standalone financial metrics.
Consolidated Results Highlights
Key figures from the consolidated financial results include:
- Total Income: Reached ₹8,205.03 million for the quarter, compared to ₹7,847.46 million in the previous quarter.
- Profit for the Period: Reported at ₹1,833.28 million.
Standalone Results Highlights
The standalone financial results reveal the following:
- Total Income: Stood at ₹4,054.09 million for the quarter, relative to ₹3,573.66 million in Q2 2026.
- Profit for the Period: Amounted to ₹1,462.40 million.
Nine-Month Performance
The cumulative results for the nine months ended December 31, 2025, indicate:
- Consolidated Total Income: ₹23,484.57 million.
- Consolidated Profit: ₹5,155.86 million.
- Standalone Total Income: ₹10,843.93 million.
- Standalone Profit: ₹3,975.14 million.
Earnings Per Share
The basic earnings per share for the quarter are reported as ₹10.96, and the diluted earnings per share are reported as ₹10.73.
Source: BSE
